Get to Know Biointaxis: Genomic Treatments and Technologies for Neurological Diseases

​Get to Know Biointaxis: Genomic Treatments and Technologies for Neurological Diseases

​Founded in 2018, Biointaxis is advancing BTX-101, a groundbreaking treatment for Friedreich's ataxia—a severe neurological disorder with no current cure.

​This session is tailored for doctors, researchers, investors, and healthcare enthusiasts, offering a deep dive into their innovative research and its potential to transform neurodegenerative disease treatment.

​Explore the details: https://capitalcell.com/en/campaign/biointaxis-2024/

​What will we cover in these sessions?

• ​What is Biointaxis?

​Discover the team behind Biointaxis, their mission, current progress with BTX-101, and future plans.

• ​Why is this project so relevant?

​Hear insights from lead scientist Antoni Matilla on the project's transformative potential, along with perspectives from lead investor Joan Mercadal, partner at Nara Capital, on why it represents a compelling investment opportunity.

• ​Q&A Session

​Get answers to your questions about Capital Cell, how it works, and how you can be part of this journey.

​Spread the Word

​Share this webinar with your network to help advance the future of gene therapy. See you soon!